Stock Price, News, Quote and Profile of GALMED PHARMACEUTICALS LTD(NASDAQ:GLMD) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

GALMED PHARMACEUTICALS LTD

NASDAQ:GLMD (5/1/2024, 3:30:01 PM)

0.3871

+0.04 (+9.97%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap2.33M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Company Info

GALMED PHARMACEUTICALS LTD

16 Tiomkin Street

TEL AVIV-YAFO 6578317

P: 97236938448

CEO: Allen Baharaff

Employees: 4

Website: https://www.galmedpharma.com

GLMD News

20 days ago - ChartmillCurious about the stocks that are showing activity before the opening bell on Thursday?

Thursday's pre-market session: top gainers and losers

21 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are worth diving into on Wednesday morning to get ready for all of the hottest news moving shares today!

21 days ago - InvestorPlaceWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024

Explore three penny stocks primed for significant growth, backed by Strong Buy ratings from Wall Street. Play it high-risk.

a month ago - InvestorPlaceGLMD Stock Earnings: Galmed Pharmaceuticals Misses EPS for Q4 2023

GLMD stock results show that Galmed Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

a month ago - Galmed Pharmaceuticals Ltd.Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

2 months ago - The Motley FoolMadrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALMED PHARMACEUTICALS LTD (GLMD)

Nasdaq Stock Screener

USA Stock Screener